In the 2022 WHO report, subtype MDS with biallelic TP53 inactivation (MDS-biTP53) was identified when there were two or more TP53 mutations or when there was one mutation with evidence of TP53 copy number loss [8]. The gene discussed is TP53; the disease is myelodysplastic syndrome.